Dow Up1.33% Nasdaq Up1.33%

More On NRI.TO



News & Info


Analyst Coverage


  • Major Holders
  • Insider Transactions
  • Insider Roster


Nuvo Pharmaceuticals Inc. (NRI.TO)

6.99 Down 0.01(0.14%) Jun 30, 3:59PM EDT
ProfileGet Profile for:
Nuvo Pharmaceuticals Inc.
7560 Airport Road
Unit 10
Mississauga, ON L4T 4H4
Canada - Map
Phone: 905-673-6980
Fax: 905-673-1842

Index Membership:N/A
Full Time Employees:41

Business Summary 

Nuvo Research Inc. operates as a life sciences company. The company operates through two segments, Nuvo Pharma and Crescita. It offers Pennsaid, a topical non-steroidal anti-inflammatory drug that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of the pain of knee osteoarthritis; and heated lidocaine/tetracaine (HLT) patch, a topical patch for surface anaesthesia of normal intact skin. The company also provides Pliaglis, a topical local anesthetic cream that provides local dermal anesthesia on intact skin prior to superficial dermatological procedures, such as dermal filler injections, pulsed-dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal. In addition, it offers WF10, a commercial product for the treatment of cancer to relieve post radiation therapy syndromes, as well as is used as an adjunct therapy for diabetic foot ulcers; and Oxoferin, a topical wound healing agent. Nuvo Research Inc. serves clients in Canada, the United States, Europe, and internationally. The company was formerly known as Dimethaid Research Inc. and changed its name to Nuvo Research Inc. in September 2005. Nuvo Research Inc. was founded in 1983 and is based in Mississauga, Canada.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Nuvo Pharmaceuticals Inc.

Key Executives 
Mr. John C. London LLB, LLM,
Chief Exec. Officer, Pres and Director
Mr. Stephen L. Lemieux BA, MMPA, CPA, CA,
Chief Financial Officer and VP
Ms. Katina K. Loucaides M.Sc., LL.B,
VP, Gen. Counsel and Corp. Sec.
Mr. Renny Ho ,
Investor Relations Officer
Mr. Patrick Gushue BA(Ed), MBA,
Director of Marketing & National Sales
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in CAD.